- First publication on utility of PRDT's prion reduction technology to further reduce risk of variant Creutzfeldt-Jakob Disease ("vCJD") from
Octaplas(R) - Octapharma sponsoring lunchtime Symposium at meeting to discuss prion
removal capacity, technical performance and product quality.
MONTREAL, Canada and CAMBRIDGE, United Kingdom, June 10 /PRNewswire-FirstCall/ - ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic") announces that Octapharma AG ("Octapharma"), one of the World's leading plasma fractionators and manufacturer of Octaplas(R) (Solvent/Detergent treated plasma), is sponsoring a Symposium during the 30th International Congress of the International Society of Blood Transfusion ("ISBT") meeting being held in Macao SAR, China. The Symposium is entitled "Prion safety and Transfusion Plasma" and will have some of the world leading authorities in Transmissible Spongiform Encephalopathy ("TSE") disease research presenting data on the utility of Pathogen Removal and Diagnostics Technologies Inc.'s ("PRDT") prion removal resin technology in this application.
The use of PRDT's proprietary ligand technology, which is licensed exclusively to ProMetic, ensures the removal of any abnormal prion proteins that may be present in donated plasma. This additional process will add another level of safety to the already established treatment protocols and is particularly relevant since there is no commercially available diagnostic test for detection of the blood-borne form of the vCJD agent.
"Over the past several months, we have forged an excellent working relationship with Octapharma," stated Dr. Steve Burton, Chief Executive Officer of ProMetic's U.K. division. "We are now concluding the scale-up phase of the development program and are extremely excited about the future potential of the product".
"We are pleased with the progress made during the development and
scale-up phase of the program,"
|SOURCE PROMETIC LIFE SCIENCES INC.|
Copyright©2008 PR Newswire.
All rights reserved